The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2015Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease
Study Rationale:
The alpha-synuclein protein forms oligomers (protein clumps) that cause toxicity in the brains of individuals with Parkinson’s disease (PD). We have developed methods that can measure... -
Research Grant, 2017Microbiome Biomarkers for Early-stage Detection and Stratification of Parkinson's Disease
Study Rationale:
Parkinson's disease (PD) research benefits from knowledge of disease-specific risk and resilience factors and elucidation of pathophysiological concepts on the emergence of... -
Research Grant, 2017Study of a Molecule to Prevent Alpha-Synuclein Clumping and Treat Parkinson's Disease
Promising Outcomes of Original Grant:
Alpha-synuclein is a sticky protein that clumps in the brains of people with Parkinson's disease (PD). In our first project funded by The Michael J. Fox Foundation... -
LRRK2 Therapeutic and Safety Initiative, 2017Efficacy and Safety of Chronic Treatment with LRRK2 Inhibitors
Study Rationale:
LRRK2 inhibitors are among the most promising in the current generation of potential novel treatments for Parkinson's disease (PD). In pre-clinical models, long-term treatment with... -
Research Grant, 2017Studying the Parkin Protein in New Pre-Clinical Models
Promising Outcomes of Original Grant:
Mitophagy is a cellular process during which damaged mitochondria, or energy generators, are broken down. Mitophagy has been suspected to malfunction in Parkinson... -
Research Grant, 2017Drawing on the Parkinson's Progression Markers Initiative (PPMI) Data to Link Changes in the PINK1/Parkin Genes with Parkinson's Disease
Study Rationale:
Two proteins, PINK1 and Parkin, prevent cell death by breaking down damaged mitochondria, cell's energy generators. This process is known as mitophagy. Mutations in PINK1/Parkin genes...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.